FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Alvotech (ALVO) received FDA approval to double production capacity for its Humira biosimilar, SIMLANDI, addressing prior inspection issues and potentially increasing U.S. supply. The company faces high debt and negative equity but analysts project significant revenue growth by 2029. The approval could impact Alvotech's earnings and operational efficiency, with varying analyst expectations on future performance.

Alvotech's shares rose 13% after the FDA approved additional U.S. manufacturing capacity for its Humira biosimilar, Simlandi. The approval doubles production capacity and suggests past plant issues may be resolved. FDA decisions on other biosimilars are expected in Q4 2026. According to the CEO, the approval effectively doubles the drug substance manufacturing capacity for U.S. supply.

Alvotech SA (ALVO) shares rose 13.5% after the FDA approved a supplement to its Biologics License Application for AVT02, allowing production in a second suite at its Reykjavik facility. This doubles manufacturing capacity for AVT02 (adalimumab-ryvk), marketed as SIMLANDI in the U.S. The FDA's July inspection closure also confirmed resolution of inspection-related matters. Alvotech expects action on other pending applications associated with the facility.

Alvotech (ALVO) stock rose 8.1% in pre-market trading after FDA approved a supplement to its Biologics License Application for AVT02, doubling U.S. manufacturing capacity. The approval resolves inspection issues and may accelerate reviews of other biosimilar applications. Analysts had recently upgraded the stock to Overweight with an $8 price target.

Alvotech (NASDAQ: ALVO) received FDA approval to expand U.S. manufacturing of AVT02 drug substance at its Reykjavik facility, doubling capacity and confirming resolution of inspection-related matters. The approval allows production in a second suite, DSM2, and supports U.S. commercial supply of AVT02, marketed as SIMLANDI®. According to the company, this milestone enhances operational flexibility and strengthens quality systems.

Alvotech (ALVO) received FDA approval to double U.S. manufacturing capacity for SIMLANDI, its biosimilar to Humira, by using a second production suite in Reykjavik. The approval follows a July 2026 inspection closure and may facilitate action on other pending FDA applications.